Paradox Immunotherapeutics Secures $10M Investment to Advance Therapies for Protein Misfolding Diseases

OBIO NewsOntario Industry Updates
Written By Arsheen Kaur

Paradox Immunotherapeutics, a pharmaceutical company focused on the development of innovative antibody therapies that treat protein misfolding diseases, recently announced a $10 million financing led by SymBiosis, an investment firm focused on advancing biotherapeutics innovations for serious and life-threatening diseases. The funding will be used to advance Paradox’s therapeutic pipeline through significant milestones in multiple indications.

Paradox Immunotherapeutics is an OBIO® member, alumnus of our BDSP™ ,CAAP®, H2BB™ and WiHI programs, and presented at the OBIO® Investment Summit.

Arsheen Kaur
Previous

OBIO® Selected by Scale AI to Provide Additional Support to Start-ups
Next

Treatment AI Acquires Rocket Doctor to Enhance Digital Health